In the absence of reliable instruments, clinicians treating mental illness use indirect, intuition-based measures. The DSM-5, the principal schema for classifying mental disorders, requires clinicians to form diagnoses based on their subjective judgments and arbitrary cut-off points. For instance, the diagnosis of major depressive disorder requires five of eight features (such as diminished interest or pleasure in activities, feelings of worthlessness, or diminished ability to think or concentrate) to persist for two weeks-based on patient or family reports.
During treatment, similarly, patients are not routinely monitored with objective assessments. Some clinicians employ self-report questionnaires, like the PHQ-9 (a nine-item scale to rate depressive symptoms), but these scales are only modestly correlated with ratings of trained observers. 2 The selfreport information is, of course, important to monitor but, like reports of chest pain or headache, usually proves insufficient. (That is, they have relatively low inter-rater reliability, do not assess patients in real world settings, and often cannot reliably attribute the effects of a given intervention).
Moreover, only 18 percent of US psychiatrists and 11 percent of psychologists routinely use symptom-rating scales or Patient-Reported Outcome Measures (PROMs) to monitor patient improvement. 3, 4 Thus, for the vast majority of patients with a mental illness, measurement often comes down to "How are you feeling?" during sporadic, brief visits in primary care. This is a bit like our example of the doctor trying to determine whether your temperature is increasing using only his or her hands and clinical experience to guide them. Or treating hypertension without a blood pressure cuff or diabetes without a glucometer.
There has been a push toward using "measurement-based care" that relies on standard rating scales and patient-reported outcomes, and good evidence that it can improve clinical outcomes. 5 But this approach has its limitations. Practically speaking, standard assessments can be difficult to implement, held back by a lack of financial support and limited personnel to administer the tests. They increase paperwork, which can burden stretched clinicians. 6 Perhaps most problematic, these measurement tools are necessarily brief and can capture only a narrow spectrum of a patient's overall state (e.g., general depression symptoms). And since they are administered infrequently, usually in the clinic, they of necessity collect one-time, or "snapshot," impressions of a person's mental health. In 2011, the World Health Organization stated: "The use of mobile and wireless technologies to support the achievement of health objectives (mHealth) has the potential to transform the face of health service delivery across the globe." 10 Since then, smartphone subscriptions have increased more than five-fold (from 856 million to more than five billion today), with projections to reach nearly seven billion by 2022. 11 There's also been astonishing growth in broadband access, even in areas without easy access to clean water. 12 Over the same period, there have been significant advances in data science too, including the advent of machine learning, which can find patterns in large data sets that were not evident using conventional statistical approaches. These developments are already transforming healthcare:
diagnostic testing is beginning to incorporate a form of machine learning called neural networks, 13 healthcare systems are taking advantage of machine learning to help triage and streamline patients
November 2018 5 through services, 14 and predictive modeling-the analysis of past and current data to forecast outcome-is using electronic health records to drive personalized medicine and improve healthcare quality. 15 The increasing ubiquity of smartphones and advent of technologies, such as home devices (Amazon Echo and Google Home) and wearables (FitBit, Apple Watch), that can act as a reliable source of measurement, combined with advances in analyzing continuous data, presents us for the first time with an opportunity to monitor brain function at population scale. This approach, called digital phenotyping, is a two-step process that works by applying machine learning to data collected from digital devices such as wearables and smartphones. 16 Obtaining the signals from the phone or wearable device is the first step. While signals from actigraphy and voice have proven to be predictive, they are also noisy and nosey.
One particularly promising approach to developing digital phenotypes of cognition that might help to move the field beyond these concerns involves data from human-computer interaction (HCI). HCIbased digital biomarkers can be generated from passively-collected, content-free interactions, like Supplementing clinical impressions and subjective, episodic assessment, digital phenotyping offers an opportunity to move towards objective, measurement-based care. For psychiatry, it could bring brain health measures to the population, and with it the ability to target care and intervention to high-risk patients, extending independence and improving productivity. Applications could include screening, early detection, disease monitoring, precise diagnosis, and a new care model based upon these.
The Challenges
Let's go back to the history of the thermometer for a moment. It wasn't because thermometers didn't exist that 19 th century physicians were reluctant to change practice. As we have seen, they had in some form been available for 200 years. Nor was it because physicians weren't aware that temperature was related to illness-that had been known since Hippocrates 2,000 years before. So, what was it that held the field back?
While physicians had a reliable instrument for measuring body heat, they didn't know what a normal temperature range was. It was only with the discoveries made by Carl Wunderlich (1868), a psychiatrist who collated nearly 100,000 observations, that data could define normal and abnormal body temperature. At that point, with the clinical utility of the thermometer evident, it was routinely adopted in clinical practice as part of a complete medical evaluation. Temperature could be used as a biomarker for disease. 26 November 2018 7 To gain widespread clinical use, digital phenotyping will need to overcome similar challenges, and a few contemporary hurdles as well.
As with body temperature, digital phenotyping needs to be tested in large, diverse populations to identify the digital biomarkers that matter. This means validating digital parameters against standard (if imperfect) measures of cognition and mood to determine which, if any, reliably give accurate, actionable data. The good news? There are already many ongoing large-scale clinical trials helping to validate this technology, and so far, the results have been promising.
But the clinical use of digital phenotyping presents ethical, legal, and social questions that the thermometer did not. 27 And there's a gap between demonstrating clinical value and achieving public trust: patients must be able to balance the benefits against real or perceived risks. No doubt building an evidence-base will be an essential step in this direction, but it will not be enough.
With the recent "techlash" against giant technology companies-consider the stir caused when Cambridge Analytica misused personal data 28 and the ongoing wave of negative news coverage for Facebook 29 -such acceptance will require more than compliance with healthcare and privacy regulations. Besides protecting user data, digital tools must offer transparency and informed consent, and when there are questions of malpractice, users must be able to hold designers, providers, companies, or otherwise, accountable. 30 To pre-empt ethical transgressions, and build trust with patients, active engagement with users in the development of new technologies and careful consideration of users concerns is essential. Tech companies must also consider limiting the range of data they are collecting and consider the potential invasiveness of their approach. The content-free digital phenotyping provided by human-computer interactions described above, for example, is likely to be more acceptable than approaches drawing upon personally identifiable information like voice or location.
Even with scientific backing and public trust, adoption and acceptance-by patients, clinicians, and healthcare systems-still presents significant challenges. Patients must want to engage with the new digital health tools. Of the more than 300,000 digital health apps currently on the market, a mere 41 Finally, we must recognize that digital phenotyping is only one piece of the puzzle. Improved health outcomes require more than detection: if the smartphone becomes a digital smoke alarm, how do we put out the fire? For mental health, many of the best treatments involve communication, skill building, and a therapeutic relationship. All of these can be done on a phone, allowing a "closed loop"
approach to mental healthcare, where digital phenotyping identifies a need and the treatment is delivered immediately by a remote clinician. The same phone can also monitor the impact of the treatment, making measurement-based care for an individual with depression or psychosis the equivalent of both the thermometer and the antibiotic for a patient with a fever.
The pioneering German psychiatrist Carl Wunderlich is said to have commented that "a physician who carried on his profession without employing the thermometer was like a blind man endeavoring to distinguish colors by feeling." 34 The same might one day be said about clinicians who don't adopt more objective measures of brain health. Whether digital phenotyping or some other method takes precedence, it is clear that practice as usual is no longer an option if we are to improve outcomes for people with mental illness. 
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